Side Effects of Lamotrigine
The most common side effects of lamotrigine include ataxia, dizziness, diplopia, somnolence, and headache, while the most clinically significant adverse effect is skin rash, occurring in 10-17% of patients, with rare but serious reactions including Stevens-Johnson syndrome and DRESS syndrome. 1
Common Neurological and General Side Effects
Based on class I evidence from multiple controlled trials, the five most frequent adverse events are 1:
- Ataxia (impaired coordination)
- Dizziness
- Diplopia (double vision)
- Somnolence (drowsiness)
- Headache
Additional commonly reported effects include nausea, vomiting, dyspepsia, and abnormal coordination 1. These neurological side effects were more prevalent when lamotrigine was combined with carbamazepine 1.
Serious Dermatological Reactions
Skin rash represents the most critical safety concern with lamotrigine:
- Incidence: 10-17% in clinical trials (compared to 6-10% with placebo) 1
- Serious reactions: Stevens-Johnson syndrome occurs in approximately 0.4% of adult patients 2
- DRESS/DIHS syndrome: Drug reaction with eosinophilia and systemic symptoms can occur, with 92% recovery rate but potential for liver failure, septic shock, or multiple organ failure in severe cases 3
Risk Factors for Rash
The risk of developing rash is significantly increased by 2:
- Concomitant valproic acid use (9.1% incidence vs. 2.8% with enzyme-inducing medications)
- Rapid dose escalation during initiation
- Higher starting doses
- History of allergies 4
Critical timing: Rash typically appears during the initiation phase in 92% of cases (12 of 13 patients) 2. The latency period ranges from 9 to 120 days, with a mean of 27.6 days 3.
Psychiatric Side Effects
Lamotrigine can induce psychiatric symptoms including 5:
- Affective switches
- Full acute psychotic episodes
- Hallucinations
Recent pharmacovigilance data identified previously unreported signals including suicidal ideation 6.
Cardiovascular and Other Serious Adverse Events
Post-marketing surveillance has revealed unexpected adverse events not documented in prescribing information 6:
- Atrial septal defects
- Brugada syndrome
- Aortic stenosis signals
Discontinuation Rates
Treatment discontinuation due to adverse events:
- 1-5% in most controlled trials at therapeutic doses 1
- 14% at higher doses (500 mg/day) 1
- 3.9% specifically due to allergic skin reactions in adult populations 2
Pediatric Considerations
In children aged 2-17 years, the adverse event profile includes 1:
- Emotional lability
- Difficulty concentrating
- Fatigue and memory deficits
- Ataxia, dizziness, tremor, nausea, and asthenia
- One case of Stevens-Johnson syndrome reported in pediatric trials
Long-Term Safety Profile
Long-term use (>6 months) is very well tolerated 4:
- Only 2 patients discontinued after 6 months due to adverse effects among 54 continuing treatment
- No difference in adverse event incidence at high maintenance doses (>200 mg) versus lower doses
- Most adverse effects occur during the early titration phase
Pregnancy-Related Considerations
Lamotrigine is considered first-line for pregnant women with epilepsy, with minimal risk of major congenital malformations compared to other antiseizure medications 7. However, altered pharmacokinetics during pregnancy require dose monitoring 8.
Critical Clinical Pitfalls to Avoid
- Do not rapidly titrate lamotrigine, especially when co-administered with valproic acid
- Screen for allergy history before initiating treatment 4
- Monitor closely during the first 2-4 months when rash risk is highest
- Immediately discontinue if serious rash develops to prevent progression to Stevens-Johnson syndrome or DRESS
- Reduce dose by 50% when adding valproic acid to prevent toxicity
Rechallenge Considerations
In patients with mild allergic reactions, rechallenge may be possible with 2:
- Smaller doses (≤12.5 mg/day)
- Slower titration
- Concomitant anti-allergic medications in select cases (3 of 13 patients successfully maintained)